Ambrx Biopharma American Stock Total Asset
Ambrx Biopharma American fundamentals help investors to digest information that contributes to Ambrx Biopharma's financial success or failures. It also enables traders to predict the movement of Ambrx Stock. The fundamental analysis module provides a way to measure Ambrx Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ambrx Biopharma stock.
Ambrx |
Ambrx Biopharma American Company Total Asset Analysis
Ambrx Biopharma's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Ambrx Biopharma Total Asset | 146.98 M |
Most of Ambrx Biopharma's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ambrx Biopharma American is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
CompetitionBased on the latest financial disclosure, Ambrx Biopharma American has a Total Asset of 146.98 M. This is 98.05% lower than that of the Biotechnology sector and 92.56% lower than that of the Health Care industry. The total asset for all United States stocks is 99.5% higher than that of the company.
Ambrx Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ambrx Biopharma's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ambrx Biopharma could also be used in its relative valuation, which is a method of valuing Ambrx Biopharma by comparing valuation metrics of similar companies.Ambrx Biopharma is currently under evaluation in total asset category among its peers.
Ambrx Fundamentals
Return On Equity | -0.37 | |||
Return On Asset | -0.19 | |||
Operating Margin | (483.51) % | |||
Current Valuation | 1.56 B | |||
Shares Outstanding | 63.29 M | |||
Shares Owned By Insiders | 2.09 % | |||
Shares Owned By Institutions | 97.91 % | |||
Number Of Shares Shorted | 1.16 M | |||
Price To Earning | 0.19 X | |||
Price To Book | 7.31 X | |||
Price To Sales | 432.96 X | |||
Revenue | 4.09 M | |||
Gross Profit | 7.4 M | |||
EBITDA | (61.75 M) | |||
Net Income | (67.06 M) | |||
Cash And Equivalents | 110.89 M | |||
Cash Per Share | 2.87 X | |||
Total Debt | 11.98 M | |||
Debt To Equity | 0.09 % | |||
Current Ratio | 4.70 X | |||
Book Value Per Share | 3.85 X | |||
Cash Flow From Operations | (57.7 M) | |||
Short Ratio | 1.21 X | |||
Earnings Per Share | 0.42 X | |||
Price To Earnings To Growth | (0.15) X | |||
Target Price | 28.5 | |||
Number Of Employees | 87 | |||
Beta | -2.36 | |||
Market Capitalization | 1.77 B | |||
Total Asset | 146.98 M | |||
Retained Earnings | (291.63 M) | |||
Working Capital | 73.92 M | |||
Z Score | 85.23 | |||
Net Asset | 146.98 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Ambrx Stock
If you are still planning to invest in Ambrx Biopharma American check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ambrx Biopharma's history and understand the potential risks before investing.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
CEOs Directory Screen CEOs from public companies around the world |